Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 2Gynecologic 2Genitourinary 2Breast 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1

Conditions

Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Oxaliplatin 3Leucovorin 3Gemcitabine 3Fluorouracil 3Bevacizumab 3trametinib 2ruxolitinib 2pertuzumab 2palbociclib 2dabrafenib 2copanlisib 2abiraterone 2Vorinostat 2Sunitinib 2Specimen Handling 2Sorafenib 2Nivolumab 2Immunoglobulin G 2HhAntag691 2Disulfides 2Dasatinib 2Capecitabine 2Bortezomib 2Afatinib 2Ado-Trastuzumab Emtansine 22C4 antibody 2venetoclax 1ulixertinib 1trastuzumab biosimilar HLX02 1temsirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × rucaparib × Plasma cell × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡